NCT06068023 (ADAPTA) is a clinical trial of Folfirinox in Ampullary Adenocarcinoma, sponsored by Fondazione Poliambulanza Istituto Ospedaliero.

Who is sponsoring NCT06068023?

NCT06068023 is sponsored by Fondazione Poliambulanza Istituto Ospedaliero.

What drugs are being tested in NCT06068023?

Interventions in NCT06068023: Folfirinox, Capox.

What condition does NCT06068023 study?

NCT06068023 studies Ampullary Adenocarcinoma.

Is NCT06068023 still recruiting?

NCT06068023 is currently recruiting now. Last updated 5 October 2023.

Last reviewed 2023-10-05 · How we verify

NCT06068023: ADAPTA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.

Recruiting now Last updated 5 October 2023

What this trial tests

trial testing Folfirinox in Ampullary Adenocarcinoma in 400 participants. Currently enrolling.

Timeline

1 July 2023

Primary endpoint
1 July 2028

1 July 2029

Quick facts

Lead sponsor	Fondazione Poliambulanza Istituto Ospedaliero
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	400
Start date	1 July 2023
Primary completion	1 July 2028
Estimated completion	1 July 2029
Sites	1 location across Italy

Drugs / interventions tested

Folfirinox (folfirinox) — full drug profile →
Capox — full drug profile →

Conditions studied

Ampullary Adenocarcinoma — all drugs for Ampullary Adenocarcinoma →

Sponsor

Fondazione Poliambulanza Istituto Ospedaliero — full company profile →

Who can join

Adults 18 to 100, any sex, with Ampullary Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype. Adjuvant therapy benefits only PB and mixed subtype patients, while prospective studies are required for validation. A study proposes tailored adjuvant treatments (CAPOX for intestinal subtype, FOLFIRINOX for PB and mixed subtypes) based on histopathology to enhance survival, also exploring molecular sub-studies for deeper insights.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Adjuvant Chemotherapy After Curative Intent Resection of Ampullary Cancer (ADAPTA): Study Protocol for a Pan-European Prospective Multicenter Double Single Arm Trial.
Uijterwijk BA, Lemmers DHL, Klei DS, Wilmink H, et al · · 2026 · PMID 41812337 · DOI 10.1097/coc.0000000000001271
Ampullary Carcinoma: Prognostic Factors and a Literature Review
Furtado I, Gião N, Gonçalves A, Vigia E, et al · · 2026

Verify or expand the search:

Other trials of Folfirinox

Trials testing the same drug.

NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
NCT05132504 — Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer · Phase 2 · recruiting
NCT04431258 — ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study · Phase 1, PHASE2 · completed
NCT04897854 — Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer · Phase 3 · unknown
NCT04594772 — Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma · Phase 2 · active not recruiting

Other recruiting trials for Ampullary Adenocarcinoma

Currently open trials in the same condition.

NCT05116072 — Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula · Phase 1, PHASE2 · recruiting

Other Fondazione Poliambulanza Istituto Ospedaliero trials

Trials by the same sponsor.

NCT07111715 — Comparison Between Artificial Intelligence and Standard Reading to Investigate Suspected Crohn Disease: the SCAI STUDY · recruiting
NCT05475041 — Perioperative Outcomes of Simultaneous Colorectal and Liver Resections · completed
NCT05478889 — Minimally Invasive Pancreatoduodenectomy for Distal Cholangiocarcinoma · completed
NCT05862948 — Accuracy of Endo-aid in Consecutive Patients Referred for Colonoscopy · NA · completed
NCT05138094 — LIVACOR Trial: Minimally Invasive LIVer And Simultaneous COlorectal Resection · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06068023 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione Poliambulanza Istituto Ospedaliero
Last refreshed: 5 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06068023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing